About ASCLETIS-B Company

Clarion is an innovative R&D driven biotechnology company listed on the Hong Kong Stock Exchange (1672.HK), covering the complete value chain from drug development to production and commercialization. The management team of Clery has deep expertise and outstanding past achievements. Under the leadership of the team, Goli focuses on the three medical fields where clinical needs have not yet been met: viral diseases, non-alcoholic steatohepatitis, and tumors, and the layout is based on a global perspective. With excellent execution, Clarion is rapidly advancing the development of drug pipelines and striving to occupy a leading position in international competition. Curie currently has a variety of drugs under development. The most advanced drug candidates include ASC22 (functional cure for hepatitis B), ASC40 (acne), ASC40 (recurrent glioblastoma), ASC40 (nonalcoholic steatohepatitis), ASC41 (nonalcoholic steatohepatitis), and ASC61 (advanced solid tumors).